Print out Parkinson's
disease treatment
guidelines*
Click here
See summaries of key clinical studies
Click here
*  You will need Adobe® Reader®  to download
this file. If you don't have
Adobe Reader, click here
for a free and secure
download.

FOR THE INITIAL AND LONG-TERM TREATMENT OF PARKINSON'S DISEASE (PD)

MIRAPEX has a well-established safety profile at all stages of Parkinson's disease

Adverse events greater than 10%

Adverse events in early and late-stage Parkinson's disease
  • Discontinuation rate due to adverse events comparable to placebo
    • - Early Parkinson's disease: 12% vs 11% (MIRAPEX vs placebo)
    • - Advanced Parkinson's disease: 12% vs 16% (MIRAPEX vs placebo)

Over a 4-year period, patients taking MIRAPEX showed no loss in cognitive function vs patients taking levodopa1

 
 

Important Information about MIRAPEX: MIRAPEX is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease (PD).

Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur. In clinical trials for early PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are nausea (28% vs. 18%), dizziness (25% vs. 24%), somnolence (22% vs. 9%), insomnia (17% vs. 12%), asthenia (14% vs. 12%), and constipation (14% vs. 6%). In clinical trials for advanced PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are postural hypotension (53% vs. 48%), dyskinesia (47% vs. 31%), extrapyramidal syndrome (28% vs. 26%), insomnia (27% vs. 22%), dizziness (26% vs. 25%), accidental injury (17% vs. 15%), hallucinations (17% vs. 4%), and dream abnormalities (11% vs. 10%).

Patients and caregivers should be informed that impulse control disorders and compulsive behaviors have been reported in patients taking dopamine agonists, including MIRAPEX.

Please see full Prescribing Information.

This information is intended for U.S. residents only.